Simon Dixon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1146405/publications.pdf

Version: 2024-02-01

90 papers

3,403 citations

201385 27 h-index 55 g-index

92 all docs 92 docs citations 92 times ranked 4640 citing authors

#	Article	IF	CITATIONS
1	Effectiveness of paramedic practitioners in attending 999 calls from elderly people in the community: cluster randomised controlled trial. BMJ: British Medical Journal, 2007, 335, 919.	2.4	287
2	Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ: British Medical Journal, 2004, 328, 254-0.	2.4	232
3	Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective. Journal of Antimicrobial Chemotherapy, 2009, 64, 1316-1324.	1.3	198
4	Clinical effectiveness of health visitor training in psychologically informed approaches for depression in postnatal women: pragmatic cluster randomised trial in primary care. BMJ: British Medical Journal, 2009, 338, a3045-a3045.	2.4	171
5	Cost effectiveness of community leg ulcer clinics: randomised controlled trial. BMJ: British Medical Journal, 1998, 316, 1487-1491.	2.4	150
6	The impact of HIV and AIDS on Africa's economic development. BMJ: British Medical Journal, 2002, 324, 232-234.	2.4	148
7	Pre-endoscopy serological testing for coeliac disease: evaluation of a clinical decision tool. BMJ: British Medical Journal, 2007, 334, 729.	2.4	128
8	Computer Therapy Compared With Usual Care for People With Long-Standing Aphasia Poststroke. Stroke, 2012, 43, 1904-1911.	1.0	119
9	Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer. JAMA - Journal of the American Medical Association, 2022, 327, 2092.	3.8	108
10	Measuring health-related quality of life in patients with venous leg ulcers. Quality of Life Research, 1999, 8, 327-336.	1.5	102
11	Parametric modelling of cost data: some simulation evidence. Health Economics (United Kingdom), 2005, 14, 421-428.	0.8	84
12	Psychological treatment for insomnia in the management of long-term hypnotic drug use: a pragmatic randomised controlled trial. British Journal of General Practice, 2003, 53, 923-8.	0.7	84
13	The Routine Collation of Health Outcomes Data from Hospital Treated Subjects in the Health Outcomes Data Repository (HODaR): Descriptive Analysis from the First 20,000 Subjects. Value in Health, 2005, 8, 581-590.	0.1	77
14	Testing the Validity of Cost-Effectiveness Models. Pharmacoeconomics, 2000, 17, 501-513.	1.7	73
15	Robot-assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy (iROC): protocol for a randomised controlled trial with internal feasibility study. BMJ Open, 2018, 8, e020500.	0.8	71
16	AIDS and economic growth in Africa: a panel data analysis. Journal of International Development, 2001, 13, 411-426.	0.9	67
17	Incorporating Carer Effects into Economic Evaluation. Pharmacoeconomics, 2006, 24, 43-53.	1.7	65
18	Predicting longer-term outcomes following psychological treatment for hypnotic-dependent chronic insomnia. Journal of Psychosomatic Research, 2003, 54, 21-29.	1.2	64

#	Article	IF	Citations
19	The Role of Patient Preferences in Cost-Effectiveness Analysis. Pharmacoeconomics, 2009, 27, 705-712.	1.7	64
20	Awareness of alcohol as a risk factor for cancer is associated with public support for alcohol policies. BMC Public Health, 2018, 18, 688.	1.2	53
21	Incorporating Process Utility into Quality Adjusted Life Years: A Systematic Review of Empirical Studies. Pharmacoeconomics, 2013, 31, 677-691.	1.7	52
22	Costâ€effectiveness of Pointâ€ofâ€care Biomarker Assessment for Suspected Myocardial Infarction: The Randomized Assessment of Treatment Using Panel Assay of Cardiac Markers (RATPAC) Trial. Academic Emergency Medicine, 2011, 18, 488-495.	0.8	49
23	Evaluating the impact of a †virtual clinic' on patient experience, personal and provider costs of care in urinary incontinence: A randomised controlled trial. PLoS ONE, 2018, 13, e0189174.	1.1	46
24	A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial. Health Technology Assessment, 2017, 21, 1-278.	1.3	42
25	Evaluation of the Cost Effectiveness of Sirolimus versus Tacrolimus for Immunosuppression Following Renal Transplantation in the UK. Pharmacoeconomics, 2006, 24, 67-79.	1.7	32
26	COST-UTILITY OF SELF-MANAGED COMPUTER THERAPY FOR PEOPLE WITH APHASIA. International Journal of Technology Assessment in Health Care, 2013, 29, 402-409.	0.2	29
27	Using contingent valuation to elicit public preferences for water fluoridation. Applied Economics, 2000, 32, 777-787.	1.2	28
28	Impact of Cognitive Behavior Therapy on Health-Related Quality of Life Among Adult Hypnotic Users With Chronic Insomnia. Behavioral Sleep Medicine, 2006, 4, 71-84.	1.1	28
29	programme as a research test-bed. A mixed-method analysis of the barriers to and facilitators of successful diabetes self-management, a health economic analysis, a cluster randomised controlled trial of different models of delivery of an educational intervention and the potential of insulin pumps and additional educator input to improve outcomes. Programme Grants for Applied Research,	0.4	28
30	2014, 2, 1-188. Economic Evaluations of Treatments for Systemic Fungal Infections. Pharmacoeconomics, 2004, 22, 421-433.	1.7	27
31	Assessing patient preferences for the delivery of different communityâ€based models of care using a discrete choice experiment. Health Expectations, 2015, 18, 1204-1214.	1.1	27
32	Cost-effectiveness of insulin pumps compared with multiple daily injections both provided with structured education for adults with type 1 diabetes: a health economic analysis of the Relative Effectiveness of Pumps over Structured Education (REPOSE) randomised controlled trial. BMJ Open, 2018, 8, e016766.	0.8	27
33	Comparison of Inhospital Mortality and Frequency of Coronary Angiography on Weekend Versus Weekday Admissions in Patients With Non–ST-Segment Elevation Acute Myocardial Infarction. American Journal of Cardiology, 2016, 118, 632-634.	0.7	26
34	Estimating the benefits of community water fluoridation using the willingness-to-pay technique: results of a pilot study. Community Dentistry and Oral Epidemiology, 1999, 27, 124-129.	0.9	25
35	Advanced access: more than just GP waiting times?. Family Practice, 2006, 23, 233-239.	0.8	25
36	Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?. Value in Health, 2016, 19, 138-144.	0.1	24

#	Article	IF	Citations
37	Multidomain Quantitative Recovery Following Radical Cystectomy for Patients Within the Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion Versus Open Radical Cystectomy Randomised Controlled Trial: The First 30 Patients. European Urology, 2018, 74, 531-534.	0.9	24
38	Cost–utility analysis of a shock-absorbing floor intervention to prevent injuries from falls in hospital wards for older people. Age and Ageing, 2013, 42, 641-645.	0.7	23
39	The relationship between staff skill mix, costs and outcomes in intermediate care services. BMC Health Services Research, 2010, 10, 221.	0.9	22
40	Impact of pelvic floor muscle training on sexual function of women with urinary incontinence and a comparison of electrical stimulation versus standard treatment (IPSU trial): a randomised controlled trial. Physiotherapy, 2018, 104, 91-97.	0.2	22
41	The financial costs of hospital care for people with diabetes who have single and multiple macrovascular complications. Diabetes Research and Clinical Practice, 2005, 67, 144-151.	1.1	20
42	The Relative Effectiveness of Pumps Over MDI and Structured Education (REPOSE): study protocol for a cluster randomised controlled trial. BMJ Open, 2014, 4, e006204-e006204.	0.8	20
43	How to Invest in Getting Cost-effective Technologies into Practice? A Framework for Value of Implementation Analysis Applied to Novel Oral Anticoagulants. Medical Decision Making, 2017, 37, 148-161.	1.2	18
44	Discrete Event Simulation-Based Resource Modelling in Health Technology Assessment. Pharmacoeconomics, 2017, 35, 989-1006.	1.7	18
45	The effectiveness of salicylic acid plasters compared with â€~usual' scalpel debridement of corns: a randomised controlled trial. Journal of Foot and Ankle Research, 2013, 6, 40.	0.7	17
46	Assessing the Expected Value of Research Studies in Reducing Uncertainty and Improving Implementation Dynamics. Medical Decision Making, 2017, 37, 523-533.	1.2	17
47	The use of willingness to pay to assess public preferences towards the fortification of foodstuffs with folic acid. Health Expectations, 2003, 6, 140-148.	1.1	15
48	Putting a value on the avoidance of false positive results when screening for inherited metabolic disease in the newborn. Journal of Inherited Metabolic Disease, 2012, 35, 169-176.	1.7	15
49	Economic analysis of the implementation of autologous transfusion technologies throughout England. International Journal of Technology Assessment in Health Care, 2005, 21, 234-239.	0.2	14
50	Resource Modelling: The Missing Piece of the HTA Jigsaw?. Pharmacoeconomics, 2015, 33, 193-203.	1.7	14
51	Impact of NHS 111 Online on the NHS 111 telephone service and urgent care system: a mixed-methods study. Health Services and Delivery Research, 2021, 9, 1-148.	1.4	14
52	Cost-effectiveness of PoNDER health visitor training for mothers at lower risk of depression: findings on prevention of postnatal depression from a cluster-randomised controlled trial. Psychological Medicine, 2019, 49, 1324-1334.	2.7	13
53	Saline in Acute Bronchiolitis RCT and Economic evaluation: hypertonic saline in acute bronchiolitis – randomised controlled trial and systematic review. Health Technology Assessment, 2015, 19, 1-130.	1.3	13
54	DiPALS: Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis – a randomised controlled trial. Health Technology Assessment, 2016, 20, 1-186.	1.3	13

#	Article	IF	CITATIONS
55	Looking inside the black box of community rehabilitation and intermediate care teams in the United Kingdom: an audit of service and staffing. Quality in Primary Care, 2009, 17, 323-33.	0.8	13
56	HIV/AIDS and development in Africa. Journal of International Development, 2001, 13, 381-389.	0.9	12
57	Pilot cluster randomised controlled trial of flooring to reduce injuries from falls in elderly care units: study protocol. Injury Prevention, 2011, 17, e7-e7.	1.2	12
58	The 5x1 DAFNE study protocol: a cluster randomised trial comparing a standard 5 day DAFNE course delivered over 1 week against DAFNE training delivered over 1 day a week for 5 consecutive weeks. BMC Endocrine Disorders, 2012, 12, 28.	0.9	11
59	When Future Change Matters: Modeling Future Price and Diffusion in Health Technology Assessments of Medical Devices. Value in Health, 2016, 19, 720-726.	0.1	11
60	Estimating Future Health Technology Diffusion Using Expert Beliefs Calibrated to an Established Diffusion Model. Value in Health, 2018, 21, 944-950.	0.1	11
61	Optimizing the Technique for Invasive Fractional Flow Reserve to Assess Lesion-Specific Ischemia. Circulation: Cardiovascular Interventions, 2019, 12, e007939.	1.4	11
62	Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa. Value in Health Regional Issues, 2019, 19, 65-74.	0.5	11
63	Patterns of graft and patient survival following renal transplantation and evaluation of serum creatinine as a predictor of survival: a review of data collected from one clinical centre over 34 years. Current Medical Research and Opinion, 2005, 21, 1793-1800.	0.9	10
64	Does self monitoring of blood glucose as opposed to urinalysis provide additional benefit in patients newly diagnosed with type 2 diabetes receiving structured education? The DESMOND SMBG randomised controlled trial protocol. BMC Family Practice, 2012, 13, 18.	2.9	10
65	Estimating informal care inputs associated with EQ-5D for use in economic evaluation. European Journal of Health Economics, 2016, 17, 733-744.	1.4	10
66	Utility values for obesity and preliminary analysis of the Health Outcomes Data Repository. Expert Review of Pharmacoeconomics and Outcomes Research, 2004, 4, 657-665.	0.7	9
67	THE RANDOM CARD SORT METHOD AND RESPONDENT CERTAINTY IN CONTINGENT VALUATION: AN EXPLORATORY INVESTIGATION OF RANGE BIAS. Health Economics (United Kingdom), 2014, 23, 1213-1223.	0.8	9
68	A model for measuring the health burden of classic congenital adrenal hyperplasia in adults. Clinical Endocrinology, 2016, 85, 361-398.	1.2	9
69	Secondary analysis and literature review of community rehabilitation and intermediate care: an information resource. Health Services and Delivery Research, 2015, 3, 1-180.	1.4	9
70	Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study. Breast, 2021, 60, 199-205.	0.9	9
71	Protocol for diaphragm pacing in patients with respiratory muscle weakness due to motor neurone disease (DiPALS): a randomised controlled trial. BMC Neurology, 2012, 12, 74.	0.8	7
72	The impact of workforce flexibility on older people's services. International Journal of Therapy and Rehabilitation, 2008, 15, 374-375.	0.1	6

#	Article	IF	CITATIONS
73	Deriving health state utilities for the numerical pain rating scale. Health and Quality of Life Outcomes, 2011, 9, 96.	1.0	6
74	Evaluating the â€real' cost-effectiveness of health technology: reconciling the public interest with patients' interests. Current Medical Research and Opinion, 2007, 23, S1-S6.	0.9	5
75	Review of Economic Submissions to NICE Medical Technologies Evaluation Programme. Applied Health Economics and Health Policy, 2016, 14, 623-634.	1.0	5
76	Predicting Productivity Losses from Health-Related Quality of Life Using Patient Data. Applied Health Economics and Health Policy, 2017, 15, 597-614.	1.0	5
77	Statistical Methods for Adjusting Estimates of Treatment Effectiveness for Patient Nonadherence in the Context of Time-to-Event Outcomes and Health Technology Assessment: A Systematic Review of Methodological Papers. Medical Decision Making, 2019, 39, 910-925.	1.2	5
78	Evaluation of the impact of a technology appraisal process in England: the South and West Development and Evaluation Committee. Journal of Health Services Research and Policy, 2003, 8, 18-24.	0.8	5
79	Comparative estimates of the financial burden to the UK health system of hospital care for people with and without diabetes in the year before death. Diabetes Research and Clinical Practice, 2004, 65, 267-274.	1.1	4
80	Health utility and survival after hospital admission with acute cardiogenic pulmonary oedema. Emergency Medicine Journal, 2011, 28, 477-482.	0.4	4
81	Economic analysis of the implementation of autologous transfusion technologies throughout England. International Journal of Technology Assessment in Health Care, 2005, 21, 234-9.	0.2	3
82	Do marginal investments made by NHS healthcare commissioners in the UK produce the outcomes they hope to achieve? Observational study. BMJ Open, 2015, 5, e009336.	0.8	2
83	Topic selection process in health technology assessment agencies around the world: a systematic review. International Journal of Technology Assessment in Health Care, 2022, 38, e19.	0.2	2
84	Developing Clinical Trial in Acute Myocardial Infarction. Therapeutic Hypothermia and Temperature Management, 2011, 1, 123-127.	0.3	1
85	Response to Letters Regarding Article, "Risk of Acute Kidney Injury After Percutaneous Coronary Interventions Using Radial Versus Femoral Vascular Access: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium― Circulation: Cardiovascular Interventions, 2014, 7, 421-421.	1.4	1
86	Response to Letter to Editor: Capturing Disutility from Waiting Time. Pharmacoeconomics, 2014, 32, 421-422.	1.7	1
87	Exploring the implementation of public involvement in local alcohol availability policy: the case of alcohol licensing decisionâ€making in England. Addiction, 2022, 117, 1163-1172.	1.7	1
88	Prioritizing and Combining Therapies for Heart Failure in the Era of Mechanical Support Devices. Interventional Cardiology Clinics, 2017, 6, 465-480.	0.2	0
89	Estimating the value of implementing reimbursement decisions: What can payers and manufacturers learn from economics?. Healthcare Management Forum, 2019, 32, 303-306.	0.6	0
90	Incorporating Process Utility into Cost-Effectiveness Analysis via a Bolt-On Domain to the SF-6D: An Exploratory Study. Applied Health Economics and Health Policy, 2021, 19, 747-756.	1.0	0